Europe

Novartis in the lead to acquire cancer drug developer MorphoSys 


Business & Finance

Reuters exclusively reported that drug maker Novartis AG (NOVN.S) is in advanced talks to acquire MorphoSys AG (MORG.DE), a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion). 

Market Impact

MorphoSys shares rose more than 40% on the news. 

Article Tags

Topics of Interest: Business & Finance

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Europe

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *